The Bolliger Group's research aims to establish novel methodology for the synthesis and functionalization of heterocycles.
Heterocycles are ubiquitous in nature, ranging from alkaloids to the bases holding together the two strands our DNA through hydrogen bonding. Heterocyclic compounds are also of crucial importance to medicinal chemists as the majority of active pharmaceutical ingredients contain at least one heterocycle in their scaffold. For example, the antifungal drug fluconazole contains two 1,2,4-triazole rings. Although significantly less common then nitrogen- and oxygen-derived heterocycles, sulfur-containing heterocyclic pharmaceuticals exist. Examples of approved drugs incorporating both sulfur and nitrogen atoms in their cycles, are olanzapine and quetiapine (both antipsychotic drugs) and clopidogrel, an anticoagulant. Many sulfur-containing heterocyclic compounds also exhibit antimicrobial or antifungal properties such as the fungicide tricyclazole and the antifungal and antiparasitic agent tiabendazole. Since bi- and tricyclic systems containing a 1,2,4-triazoles joined with a sulfur heterocylce exhibit a wide range of biological activity including antimicrobial, antifungal, antioxidant, anti-inflammatory, and anticancer activity, much of the research in the Bolliger group focuses on developing new methods to prepare both known and novel fused heterocyclic scaffolds.
A non-conclusive list of (other) areas of interest to the Bolliger Lab:
Heterocyclic Chemistry
Catalysis (Transition Metal and Supramolecular Catalysis)